Targeted therapeutic protocol and pharmaceutical monitoring for ALK-positive advanced non-small cell lung cancer:one case report
Anaplastic lymphoma kinase-tyrosine kinase inhibitors(ALK-TKIs)have been a first-line option for ALK-positive advanced non-small cell lung cancer.A large series of adverse reactions occur while benefiting patients.This review summarized the pharmaceutical cares for intolerable nausea and vomiting after crizotinib dosing in one patient of ALK-positive lung cancer.After switching to ensartinib,there was diffuse epidermal peeling of whole body.A clinical pharmacist assisted physicians in han-dling adverse reactions and implementing pharmaceutical monitoring.Follow-up intervention was both efficacious and well-tolerated.It fully exemplified the role of clinical pharmacists in individualized treatment of tumor patients.It provided practical ref-erences for a proper management of such adverse drug reactions.
non-small cell lung canceranaplastic lymphoma kinase(ALK)targeted therapycrizotinibensartinibpharma-ceutical care
NETL
NSTL
万方数据
